Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. - Wikidata - awgldk - TriplyDB

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

http://www.wikidata.org/entity/Q30387739

about

Can follicular helper T cells be targeted to improve vaccine efficacy?B Cells and Functional Antibody Responses to Combat Influenza Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza viruses H5N1 vaccines in humans Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination Rapid profiling of the antigen regions recognized by serum antibodies using massively parallel sequencing of antigen-specific libraries Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.IgM, IgG, and IgA antibody responses to influenza A(H1N1)pdm09 hemagglutinin in infected persons during the first wave of the 2009 pandemic in the United States Considerations for the rapid deployment of vaccines against H7N9 influenza.Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.Influenza vaccines: a moving interdisciplinary field.Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.Influenza vaccine immunology.Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets A novel hemagglutinin protein produced in bacteria protects chickens against H5N1 highly pathogenic avian influenza viruses by inducing H5 subtype-specific neutralizing antibodies Inactivated influenza vaccines: recent progress and implications for the elderly.Immunity to seasonal and pandemic influenza A viruses A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.MF59 adjuvant: the best insurance against influenza strain diversity.MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines.H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender.Influenza virus H1N1pdm09 infections in the young and old: evidence of greater antibody diversity and affinity for the hemagglutinin globular head domain (HA1 Domain) in the elderly than in young adults and children.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

P2860

Q26753848-E2A72A18-50F9-4403-8021-55D5EB6118E1 Q26801639-CC662A37-F8D0-4338-8C52-9FD097B3D232 Q26825532-9CD17C49-B315-42E7-85DD-24ADFA4ADE8E Q27000896-E3A8C8DD-7A19-4D5C-AE64-CE3027659CE1 Q28603849-F956EA9F-C129-4AC8-BBE3-2768E65E8F59 Q28730561-662C97EA-12A8-45E5-A02B-BB226CDF8F16 Q28742771-17FE267D-1329-41EF-9B0F-74ED5AC5DE74 Q28743086-C4BF3C60-1494-4532-8A15-BDDE8B69226C Q28743596-CA928E5A-4950-4D89-9F1F-7521603BF69C Q29048193-3267D13B-E57D-4352-B915-F836464D83E7 Q30204573-B6FF66EA-AE2C-4EA9-85BC-AE2DA2E29D44 Q30223941-887FBBB5-4AA4-4920-9F42-F4D5521CAEB0 Q30353708-9051CCEC-F554-4CD2-9EC1-BD8FBC5019AE Q30360610-5205953A-6CB7-4F53-9B8B-DA1231366BCB Q30361644-5888F496-8CDC-466E-9944-7838CA0B1138 Q30362883-922B5E6F-A0BE-4020-848F-E7EF675D543A Q30362980-A43BEB9A-DDC1-4CF7-9CC7-C6BBA49EB0EC Q30364635-2100651A-6D3B-4742-954B-AD19CED66774 Q30366045-A7648149-7D11-4295-BD68-5E23033EEE31 Q30367695-854F5BBE-9F80-48BB-B30D-48FECF254167 Q30371162-E8E5079D-5340-408B-A33A-68FB59464EDC Q30374665-8197A5A2-BCFD-4184-B932-CEAED4694B79 Q30375380-F9D6D8AB-975C-46EB-B0AF-BF3A8FEB61C5 Q30391443-D22D1355-9AB0-4741-AD1E-F63792916903 Q30395263-E9573D7D-EF11-4911-B8CB-1608EB215A87 Q30396343-04AD6292-9176-438E-964F-C795C69D3C65 Q30398035-D63C8225-4869-42D4-8DCD-AEF4F69F1272 Q30398277-E77AFDC5-6985-43E6-9DC4-F0777CCA1B4E Q30398811-71000F37-CE45-401B-8971-1F3DAA8B983E Q30399057-355D496A-9EE2-471B-AF61-20F84A869046 Q30399357-602184CF-0786-45DD-BF7B-AC75A4A99A0E Q30400550-336A644D-4BF4-47A7-BEA6-F4BC6BE4C89E Q30401247-33A1F95F-44D8-4FF0-9CA7-424AD37C68B7 Q30401398-3E1DE70C-BBB3-4A30-BBD0-5243B1E7CF49 Q30402018-29F72040-3F0D-4AEF-940F-1BAB1F952B6F Q30403361-BED8C826-822B-4234-9CF7-775C1DB8A9F1 Q30406365-93B226B7-FC95-4D57-AAAD-12A3E9B775D5 Q30411189-9659E563-4CD7-47E2-9F86-7E015058F1F1 Q30413677-C6C1767B-B11F-41D6-8EE4-2899AE336C9D Q30413695-5DB71BED-D83A-4321-BBC7-012FCB01E467

P2860

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.

http://www.wikidata.org/entity/Q30387739

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@ast

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@en

type

label

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@ast

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@en

prefLabel

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@ast

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@en

P1433

Q30387739-EF5C2F95-4413-45DC-A459-6C2E6AAF67A6

P1476

Q30387739-DD6CBE07-B53E-4C9B-A3E8-D27C870FE6E1

P2093

Q30387739-09F16C61-1EDC-46C2-AC5A-DDDC40BE9CBF

Q30387739-11A99D08-7C78-4CFB-860A-8E11EFB56A67

Q30387739-2953397E-871C-4398-91D6-9B8A48386297

Q30387739-538DB520-4815-45AC-B410-494AEB9F4F9B

Q30387739-53F446A2-E092-4F32-8751-CAAF1B16A684

Q30387739-8735A1D5-AB53-4DD2-87AF-F37AE61F4EDD

Q30387739-9446383C-F120-4485-811B-3B6F826A9604

Q30387739-B65BD3C6-C02C-4E15-B992-5864F2695ED8

Q30387739-FC2EA11A-A47A-4274-9A05-45148D8F3786

P2860

Q30387739-1F9296AB-49CC-49CA-9752-9789BE0E00A5

Q30387739-28787077-FA0C-4D8E-9A6D-21EB911F9BC3

Q30387739-34F44E97-CD69-45C6-B12C-BC880EA753C3

Q30387739-46555031-3032-48B9-BAF7-F17FC63ADE39

Q30387739-480975C7-5F78-4940-B6CC-9737260442C4

Q30387739-53A13443-5534-46AE-8907-47EC3AEB0EEE

Q30387739-59092C80-1384-4557-99FB-FAAD58F49E06

Q30387739-5F4D9F2B-0D80-4DF4-A872-B474BD8659F9

Q30387739-97C55729-5E22-400E-871A-E67E1799D766

Q30387739-C17C6075-BAD2-4A8C-B279-9FC042CD8ACF

P304

Q30387739-59E078FF-11E3-441F-BCE4-3F1EC4BDC534

P31

Q30387739-C2E0DB0A-392A-462B-886C-59B61022D70B

P356

Q30387739-F744054B-B804-4F57-BDE4-B35117EF5324

P407

Q30387739-E00265C5-8AEC-4B61-986B-F0FF3451713B

P433

Q30387739-5F731611-903F-4125-BA0F-CCC77EF1D915

P478

Q30387739-ABFE3E18-60CC-4952-B542-558881EB7954

P50

Q30387739-25AB999D-418C-4729-9E52-FE61D1A7D880

Q30387739-4CA10B02-0583-4262-B43F-5E79E6588306

P577

Q30387739-7EFF1061-22B9-487A-9233-AE6C95C8F745

P698

Q30387739-2C4D1303-97AA-41E6-827F-33BA5DB84A9B

P921

Q30387739-0ED5A80A-CD48-4601-9678-6EFB8AE3E2EA

Q30387739-F0168F7F-70A7-4748-AFEC-4E4F8E20E645

P356

SCITRANSLMED.3000624

P1433

Science Translational Medicine

P1476

Vaccines with MF59 adjuvant ex ...... ic avian H5N1 influenza virus.

@en

P2093

Agnieszka Honorkiewicz

http://www.w3.org/2001/XMLSchema#string

Flora Castellino

http://www.w3.org/2001/XMLSchema#string

Giuseppe Del Giudice

http://www.w3.org/2001/XMLSchema#string

Hana Golding

http://www.w3.org/2001/XMLSchema#string

Jody Manischewitz

http://www.w3.org/2001/XMLSchema#string

Lisa R King

http://www.w3.org/2001/XMLSchema#string

Michael T Rock

http://www.w3.org/2001/XMLSchema#string

Surender Khurana

http://www.w3.org/2001/XMLSchema#string

Wanida Chearwae

http://www.w3.org/2001/XMLSchema#string

P2860

Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans

Emergence of European avian influenza virus-like H1N1 swine influenza A viruses in China.

Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors.

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine.

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.

P304

15ra5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000624

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Kathryn M. Edwards

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20371470

http://www.w3.org/2001/XMLSchema#string

P921